Researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine have developed an orally administered drug to disrupt prostate cancer cells’ metabolism and deliver the chemotherapy agent cisplatin directly into treatment-resistant prostate cancer cells.
ArteraAI has validated its first multimodal artificial intelligence digital pathology-based post-radical prostatectomy biomarker for stratifying risk of metastasis and identifying differential absolute benefit for the addition of hormone therapy to salvage radiation therapy in radical prostatectomy patients with biochemical recurrence.
